Introduction
============

Hypothyroidism is an endocrine disorder characterized by deficient hormone production or defective hormone action at the tissue level.[@b1-cmwh-8-2015-001] The prevalence is 2%--15% in the general population.[@b2-cmwh-8-2015-001] According to a population-based study conducted in South India, the prevalence of hypothyroidism in adults was found to be around 3.9%.[@b3-cmwh-8-2015-001]

The notorious effects of thyroid disorders on bone metabolism have been a topic of debate over the years. Although both osteoclastic and osteoblastic activities increase with elevated concentrations of thyroid hormones, the osteoclastic activity is predominant, with consequent bone loss.[@b4-cmwh-8-2015-001],[@b5-cmwh-8-2015-001]

Thyroid hormones have been reported to reduce bone mineral density (BMD) in women and cause secondary osteoporotic changes.[@b6-cmwh-8-2015-001],[@b7-cmwh-8-2015-001] Meta-analysis of published reports has indicated that a 1% bone loss per year occurs during the postmenopausal period in women who were administered suppressive doses of thyroxine (T4).[@b6-cmwh-8-2015-001]--[@b8-cmwh-8-2015-001]

Osteoporosis is an ailment characterized by decreased bone strength. It is more prevalent among postmenopausal women, although it can also occur in men and women with underlying conditions such as hormone deficiencies and other risk factors associated with bone demineralization.[@b6-cmwh-8-2015-001],[@b9-cmwh-8-2015-001],[@b10-cmwh-8-2015-001] The relation between thyroid disorders and osteoporosis was first recognized 100 years ago.[@b9-cmwh-8-2015-001] Most of the studies on bone changes related to thyroid disorders have been carried out in postmenopausal women and post-thyroidectomy patients on suppressive doses of thyroxine.[@b7-cmwh-8-2015-001],[@b8-cmwh-8-2015-001],[@b10-cmwh-8-2015-001],[@b11-cmwh-8-2015-001] Reports on replacement doses and their effects on bone metabolism are limited.

Assessment of bone status has always been dominated by radiological diagnosis. Biomarkers of bone metabolism have always struggled to make their place, in spite of their important roles being proven over and again. Specific biochemical markers of bone turnover, such as human osteocalcin, bone alkaline phosphatase, and urinary deoxypyridinoline crosslinks and type 1 collagen-related peptide are available, with a number of applications including selection of patients for therapy, monitoring the effectiveness of therapy, prediction of bone loss, and prediction of fracture risk.[@b1-cmwh-8-2015-001],[@b12-cmwh-8-2015-001] Osteocalcin is a major bone matrix protein, with serum range from 5 ng/mL to 27 ng/mL. After production, it is partly incorporated into the bone matrix and the remainder is found in the blood circulation.[@b13-cmwh-8-2015-001] A number of studies show that the circulating levels of osteocalcin reflect the rate of bone formation.[@b6-cmwh-8-2015-001],[@b14-cmwh-8-2015-001]--[@b16-cmwh-8-2015-001] Serum calcium and phosphorus levels are also indirect markers of bone status. There are a few studies where elevation of serum calcium and phosphorus are seen in diseases associated with bone resorption.[@b7-cmwh-8-2015-001]--[@b9-cmwh-8-2015-001]

In radiological terms, osteoporosis is defined as bone density that falls 2.5 standard deviations below the mean for young healthy adults of the same gender. It is also referred to as a *T-score* of −2.5.[@b17-cmwh-8-2015-001] The advent of newer technologies such as quantitative ultrasound (QUS) has succeeded in providing solutions that avoid radiation. It has been proven to be a good radiological predictor of fracture risk.[@b18-cmwh-8-2015-001] QUS provides information on bone density, elasticity, and structure, in addition to detecting bone loss.[@b16-cmwh-8-2015-001],[@b18-cmwh-8-2015-001]

Data on the effect of levothyroxine replacement therapy in premenopausal women are very limited. Thus, a combination of parameters, such as serum osteocalcin, calcium, and phosphorus along with BMD assessment, were tried in our study to help assess bone remodeling in premenopausal hypothyroid women on levothyroxine therapy.

Materials and Methods
=====================

A case--control study was conducted at a tertiary-level hospital from November 2011 to October 2012. A total of 75 premeno-pausal women in the age group of 30--45 years were selected and grouped as follows: 25 hypothyroid women on levothyroxine (100--200 μg/day) for minimum 5 years (Group I), 25 newly diagnosed hypothyroid women (Group II), and 25 euthyroid women (Group III). The study was approved by the research and ethics committee of Kasturba Medical College, Manipal University. Informed consent was obtained from all the subjects. The study was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Patients excluded were post-thyroidectomy patients on suppressive doses of levothyroxine; patients with bone and joint disorders; known cases of hypertension, diabetes, and dyslipidemia; patients on steroids, oral contraceptive pills, and anticonvulsant therapy; patients on vitamin D and calcium supplements; patients with vitamin D deficiency, parathyroid disorders, long-term immobilization, and malignancy; pregnant/lactating women; and hysterectomized patients.

Blood from each subject was collected in sterile plain and ethylenediaminetetraacetic acid-containing vacutainer tubes. Serum and plasma were separated and analyzed biochemically. Estimation of serum calcium was done by the o-cresolphthalein method,[@b19-cmwh-8-2015-001] serum phosphorus was estimated using ammonium phosphomolybdate Ultra violet method in the Roche Hitachi P.800/917 analyzer.[@b19-cmwh-8-2015-001] Estimation of Osteocalcin was done by electrochemiluminescence immunoassay based on the sandwich principle using Elecsys N-MID-Osteocalcin kits[@b20-cmwh-8-2015-001] (Roche Diagnostics, Mannheim, Germany) in Roche E170, e411 analyzer.

BMD of the radius bone in the forearm was measured using portable QUS. Patients' height and weight were recorded for calculation of body mass index.

Statistical analysis
--------------------

The sample size calculation was done by the statistician as per the university-approved protocol. Statistical analysis was done using analysis of variance (ANOVA) and Tukey's method. Correlation between bone markers and thyroid hormones was determined by Pearson's correlation.

Results
=======

The baseline characteristics in [Table 1](#t1-cmwh-8-2015-001){ref-type="table"} did not show any significant difference between the euthyroid and newly diagnosed hypothyroid groups. The data of the three groups were analyzed by ANOVA and Tukey's test. Women between 30 years and 45 years of age were considered for selection, but the mean age of the women in groups I, II, and III was 40.4 ± 5.09, 37.88 ± 5.82, and 38.08 ± 6.06 years, respectively. Characteristics such as age, height, weight, and time since menarche showed no significant difference between the levothyroxine therapy group (Group I) and the other two groups. History of fractures was negative in all three groups. The women in the treatment group (Group I) were of average age of 40.4 ± 5.09 years, which was higher compared to that in the other two groups, but not statistically significant.

Average dosage of the group was 125 μg/day. There were two cases whose dosage was above 150 μg but their levels did not show significant elevation, probably due to the smaller duration of treatment.

The euthyroid women had a normal range (2.40 ± 0.85 international units \[IU\]/mL), newly diagnosed hypothyroid women had elevated TSH levels (11.96 ± 13.18 IU/mL), and the group on long-term thyroxine therapy had almost normalized TSH levels (3.93 ± 2.99 IU/mL). The TSH values showed a statistically significant difference among the three study groups (*P*-value: \<0.001).

In [Table 2](#t2-cmwh-8-2015-001){ref-type="table"} and [Figure 1](#f1-cmwh-8-2015-001){ref-type="fig"}, osteocalcin levels in the patients on long-term levothyroxine therapy were significantly higher (26.5 ± 7.8 ng/mL) than the levels in the newly diagnosed hypothyroid women and the euthyroid group. The serum levels of calcium and phosphorus were significantly higher in the treatment group compared to the other two groups. BMD showed definite features of osteopenia (*T*-score = −2.26 ± 0.5) among the women in the treatment group, while it was within the normal range for the newly diagnosed and euthyroid groups, as shown in [Table 2](#t2-cmwh-8-2015-001){ref-type="table"}. The other observation evident in [Table 3](#t3-cmwh-8-2015-001){ref-type="table"} was the effect of duration of treatment on the marker levels; osteocalcin and calcium levels, *T*-score, and *Z*-score were significantly higher in the women of the treatment group who were taking levothyroxine for \>10 years than the same in cases undergoing treatment for \<10 years.

In the current study, there was no significant correlation between thyroid hormones and osteocalcin.

Discussion
==========

The objective of this study was to analyze the bone changes in premenopausal women and compare these changes among the euthyroid, newly diagnosed hypothyroid, and hypothyroid on levothyroxine therapy groups by estimation and comparison of their plasma osteocalcin, serum calcium and phosphorus levels, and BMD. As deducted from [Table 1](#t1-cmwh-8-2015-001){ref-type="table"}, the subjects did not show significant difference in their age, height, and weight and were therefore well matched. None of the subjects included in the study had a history of fractures ([Table 1](#t1-cmwh-8-2015-001){ref-type="table"}), implying that none of them had significant weak bones that could cause pathological fractures.

The patients were selected and categorized based on their thyroid profiles and thus showed a significant difference in their TSH levels ([Table 4](#t4-cmwh-8-2015-001){ref-type="table"}), as per the selection criteria. The patients on long-term levothyroxine therapy (100--200 μg/day) had TSH levels in the normal range, as they could have been restored to the euthyroid state.

In the current study, cases of hypothyroidism on levothyroxine treatment were found to show changes in their bone turnover, as reflected by their *T*-score, plasma osteocalcin levels, and serum calcium and phosphorus levels, in comparison to the euthyroid and newly diagnosed cases, as seen in [Table 2](#t2-cmwh-8-2015-001){ref-type="table"}.

Many hypotheses have been put forth to explain the deteriorating effects of thyroid disorders on bone metabolism. Some researchers believe that TSH may also have a direct effect on bone formation and bone resorption, mediated via the TSH receptor on osteoblast and osteoclast precursors, blaming the hypothyroidism itself as a cause of bone loss,[@b21-cmwh-8-2015-001],[@b22-cmwh-8-2015-001] while a larger group believes that not TSH, but thyroid hormones directly stimulate bone resorption. This action may be mediated by nuclear triiodothyronine (T3) receptors, which have been found in rat and human osteoblast cell lines and in osteoclasts derived from an osteoclastoma. Thyroid hormone indirectly promotes osteoclast formation and activation by inducing the expression of cytokines, prostaglandins, and the receptor activator of nuclear factor NF-kB ligand.[@b23-cmwh-8-2015-001]--[@b25-cmwh-8-2015-001] Experimental studies in mice lacking either the thyroid receptor-α or thyroid receptor-β suggest that bone loss is mediated by the thyroid receptor.[@b26-cmwh-8-2015-001]--[@b28-cmwh-8-2015-001]

The third theory is that bone could be responding to the higher serum T4 concentrations achieved with T4 replacement, as a meta-analysis demonstrated reduced bone density in premenopausal women receiving replacement T4 therapy but not in postmenopausal women.[@b26-cmwh-8-2015-001] In the current study, the T3 and T4 levels in the treated group were found to be in the normal range, which contradicts the finding of this meta-analysis. However, because this was not a randomized controlled trial and we included patients on treatment for \>5 years, possibilities of normalization of thyroid status may not be negated. In such cases, initial dramatic sequence of events in the initial years of therapy may have led to resorptive changes. Meir et al,[@b29-cmwh-8-2015-001] in their randomized controlled trial, concluded with a hypothesis that may explain our findings. They evaluated the effect of L-thyroxine (L-T4) treatment on bone metabolism in patients with subclinical hypothyroidism by measuring 24- and 48-week changes in markers of bone formation and resorption and BMD by dual-energy x-ray absorptiometry. They concluded that physiological L-thyroxine therapy accelerates bone turnover, reflecting early activation of bone remodeling units in the initial replacement of subclinical hypothyroidism. They also concluded that the observed bone loss could be an adaptive mechanism to the decreased bone turnover in preexistent hypothyroidism, and not as L-thyroxine-induced bone loss. There are other studies that support the same findings.[@b30-cmwh-8-2015-001],[@b31-cmwh-8-2015-001] BMD values indicate osteopenia (*T*-score = −2.26 ± 0.5) among the women in the treatment group, while the values were within the normal range for the newly diagnosed and euthyroid groups. Terri et al[@b32-cmwh-8-2015-001] stated in their study that women treated with L-thyroxine at supraphysiologic dosages over a long term may be predisposed to decreased bone density in the hip, which may increase the risk of age-related bone loss. However, a study by Franklin et al[@b9-cmwh-8-2015-001] did not show any significant changes in the BMD values in premenopausal women on replacement doses of levothryoxine.

Our study showed increased resorption in the forearm, specifically the radius, which aligns with the findings of Vestergaard et al[@b33-cmwh-8-2015-001] and Tremolliers et al[@b34-cmwh-8-2015-001] in their studies. According to a study by Kung et al,[@b35-cmwh-8-2015-001] primary hypothyroidism patients on levothyroxine therapy have demonstrated low values for femoral and radial BMDs. Multiple studies suggest that there is a site-dependent resorption in long-term levothyroxine therapy, and it is not generalized to the whole skeleton.[@b5-cmwh-8-2015-001],[@b25-cmwh-8-2015-001],[@b27-cmwh-8-2015-001]

In our study, osteocalcin levels were significantly higher (26.5 ± 7.8 ng/mL) in patients on long-term levothyroxine therapy than in the newly diagnosed hypothyroid women and the euthyroid group, indicative of an overall increase in the bone remodeling and increased activation of osteoblastic as well as indirect activation of osteoclastic activity.

Studies by Atalay et al[@b36-cmwh-8-2015-001] and others[@b37-cmwh-8-2015-001],[@b38-cmwh-8-2015-001] have confirmed that osteocalcin was among the best predictors of osteoporosis. In a study by Harikumar et al,[@b39-cmwh-8-2015-001] osteocalcin had significant correlation with BMD in postmenopausal women with osteoporosis, which was not found in our study.

In our study, there were significant differences in both the calcium and the phosphorus levels between the treatment group and the other two groups. However, the serum calcium and phosphorus levels were only slightly above the normal range in the treatment group. The possible explanation is that because osteocalcin is elevated in this group, it increases the bone turnover of calcium and phosphorus, resulting in the latter's release into the serum.[@b40-cmwh-8-2015-001] Serum calcium and phosphorus levels have been used routinely in the past for bone status assessment; hence, it was evaluated in this study.[@b17-cmwh-8-2015-001],[@b41-cmwh-8-2015-001],[@b42-cmwh-8-2015-001] There are a few studies that have found significant hypercalcemia in suppressive thyroid therapy.[@b5-cmwh-8-2015-001],[@b7-cmwh-8-2015-001] Studies state that patients on replacement doses of levothyroxine do not show significant increase in serum calcium or phosphorus levels individually.[@b6-cmwh-8-2015-001],[@b41-cmwh-8-2015-001],[@b42-cmwh-8-2015-001]

In the current study, it was found that osteocalcin, calcium levels, *T*-score, and *Z*-score were significantly higher in the treatment group who were on levothyroxine therapy for \>10 years than in the cases undergoing treatment for \<10 years' duration ([Table 3](#t3-cmwh-8-2015-001){ref-type="table"}).

Long-term L-thyroxine therapy for a minimum of 5 years was found to be associated with decreased hip bone density in premenopausal women, according to Terri et al[@b32-cmwh-8-2015-001] and other studies,[@b43-cmwh-8-2015-001],[@b44-cmwh-8-2015-001] which agrees with our findings. According to a study by Sijanovi[@b6-cmwh-8-2015-001] and others,[@b27-cmwh-8-2015-001],[@b45-cmwh-8-2015-001] women on 10 years of levothyroxine therapy show a very significant loss of bone, compared to the results in women on shorter duration of treatment, though there are changes starting from the first year of treatment. Our study showed significant bone loss in women of the treatment group of \>10 years when compared to the lesser-duration group, which aligns very well with these studies.

Limitations of the study were that we did not evaluate the vitamin D and parathormone levels in the subjects, and these could have had an effect on the bone status of the subjects in case of vitamin D deficiency and hypoparathyroidism. However, because we excluded these conditions by detailed clinical history and previous laboratory reports, as well as estimated the calcium and phosphorus levels in all the subjects, the confounding effects of these factors have been minimized.

Conditions that could have a direct or indirect effect on the bone status of the patients have been excluded, thereby helping in correlating better the bone changes in the patient group with the effects after treatment. We have not only evaluated the bone turnover by using the biochemical markers but have also assessed it through radiological examination.

Estimation of markers of bone resorption help in getting a complete picture of the bone status. We intend to carry out a complete analysis of both bone formation and bone resorption markers in the treatment group. Follow-up of these subjects into menopause and evaluation of their risk for fractures can be done.

Conclusion
==========

To summarize, hypothyroid women on long-term levothyroxine therapy showed signs of increased bone turnover and increased resorptive changes, though not frank osteoporosis. Hence, we conclude that careful monitoring of bone status in patients receiving thyroxine replacement therapy may be advocated, in an attempt to avoid possible negative outcomes of overtreatment.
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###### 

Baseline characteristics of the study groups (mean ± standard deviation).

  CHARACTERISTICS              ON TREATMENT GROUP I (N = 25)   NEWLY DIAGNOSED GROUP II (N = 25)   EUTHYROID GROUP III (N = 25)   *P*-VALUE
  ---------------------------- ------------------------------- ----------------------------------- ------------------------------ -----------
  Age (years)                  40.4 ± 5.09                     37.88 ± 5.82                        38.08 ± 6.06                   0.252 NS
  Years since menarche         35.4 ± 3.83                     33.4 ± 3.65                         32.1 ± 2.87                    0.142 NS
  Height (cm)                  154.2 ± 2.23                    155.51 ± 3.1                        153.2 ± 2.67                   0.665 NS
  Weight (kg)                  61.2 ± 5.89                     59.30 ± 5.43                        59.24 ± 6.20                   0.087 NS
  History of fractures (Y/N)   No                              No                                  No                             --

**Note:** *P*-value \<0.05 is considered significant.

**Abbreviations:** N, number of subjects; NS, not significant; Y/N, yes/no.

###### 

Comparison of bone markers among the three groups.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  VARIABLES              ON TREATMENT (GROUP I)\   NEWLY DIAGNOSED (GROUP II)\   EUTHYROID (GROUP III)\   *P*-VALUE
                         N = 25                    N = 25                        N = 25                   
  ---------------------- ------------------------- ----------------------------- ------------------------ ------------------------------------------------------------
  Osteocalcin, (ng/mL)   26.45 ± 7.87              19.75 ± 8.1                   18.21 ± 5.3              \<0.0001[\*\*](#tfn4-cmwh-8-2015-001){ref-type="table-fn"}

  Calcium, (mg/dL)       11.14 ± 0.41              10.15 ± 0.66                  10.52 ± 0.60             \<0.0001[\*\*](#tfn4-cmwh-8-2015-001){ref-type="table-fn"}

  Phosphorus, (mg/dL)    4.94 ± 0.95               4.18 ± 0.66                   4.29 ± 0.86              0.004\*

  *T*-score              −2.27 ± 0.50              0.02 ± 1.07                   0.16 ± 1.29              \<0.0001[\*\*](#tfn4-cmwh-8-2015-001){ref-type="table-fn"}

  *Z*-score              −1.79 ± 0.47              1.17 ± 1.05                   0.95 ± 0.93              \<0.0001[\*\*](#tfn4-cmwh-8-2015-001){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** N, number of subjects in the group; *T*-score and *Z*-score are expressed as standard deviations (SDs) below mean;

*P*-value \<0.001 is very significant.

###### 

Effect of duration of treatment on bone markers and BMD scores.

  ----------------------------------------------------------------------------------------------
  VARIABLES             ON LT- n4 SINCE 5--10 YEARS\   ON LT-4 SINCE 11--15 YEARS\   *P*-VALUE
                        N = 16                         N = 9                         
  --------------------- ------------------------------ ----------------------------- -----------
  Osteocalcin (ng/mL)   24.62 ± 6.97                   32.64 ± 8.81                  0.03

  Calcium (mg/dl)       10.96 ± 0.46                   11.6 ± 0.25                   0.007

  Phosphorus (mg/dl)    4.99 ± 0.98                    4.64 ± 0.71                   0.465 NS

  *T*-score             −2.10 ± 0.41                   −2.88 ± 0.27                  0.001

  *Z*-score             −1.64 ± 0.38                   −2.34 ± 0.32                  0.001
  ----------------------------------------------------------------------------------------------

**Notes:** N, number of subjects in the group; *T*-score and *Z*-score are expressed as standard deviations (SDs) below mean; \*\**P*-value \<0.001 is very significant.

###### 

Thyroid profiles of the three groups.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  VARIABLE                ON TREATMENT GROUP I\   NEWLY DIAGNOSED GROUP II\   EUTHYROID GROUP GROUP III\   *P*-VALUE
                          N = 25                  N = 25                      N = 25                       
  ----------------------- ----------------------- --------------------------- ---------------------------- ------------------------------------------------------------
  TSH (0.4--4.2 μIU/mL)   3.93 ± 2.99             11.96 ± 13.18               2.40 ± 0.85                  \<0.0001[\*\*](#tfn7-cmwh-8-2015-001){ref-type="table-fn"}

  T3 (0.7--2.04 ng/mL)    1.22 ± 0.33             1.19 ± 0.32                 1.46 ± 0.52                  0.01[\*](#tfn6-cmwh-8-2015-001){ref-type="table-fn"}

  T4 (4.6--10.5 μg/dL)    8.27 ± 2.3              7.28 ± 2.07                 8.53 ± 2.00                  0.07
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*-value \<0.05 is considered significant;

*P*-value \<0.001 is very significant.

**Abbreviations:** N, number of subjects; TSH, thyroid-stimulating hormone; T~3~, triiodothyronine; T~4~, tetraiodothyronine.
